DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Defense Health Agency Contracting Activity - DHACA · Opportunity HT942526ALSRPTDA
≈ 6 awards expected
Who can apply
- Unrestricted
About this opportunity
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
Portfolio context — this listing covers more than this opportunity
This opportunity is funded under Assistance Listing 12.420 (“Military Medical Research and Development”), a broad federal program that made about 1078 new awards per year over the last five fiscal years (median award $846k). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.
Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number. CDMRP publishes cumulative applications received and funded per program — source.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| A Science of Science Approach to Analyzing and Innovating the Biomedical Research Enterprise | U.S. National Science Foundation | September 9, 2026 0d left | $250k | Nonprofits |
| Public Wireless Supply Chain Innovation Fund Grant Program – Solutions for AI-Native RAN | National Telecommunications and Information Admini | September 9, 2026 0d left | — | |
| Computer and Information Science and Engineering (CISE): Future Computing Research | U.S. National Science Foundation | September 10, 2026 1d left | $12M | |
| DoW Vision, Mentored Clinical Research Award | Defense Health Agency Contracting Activity - DHACA | September 10, 2026 1d left | — | Nonprofits |